Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
8.86
+0.19 (2.19%)
May 22, 2026, 11:53 AM EDT - Market open
Immix Biopharma Employees
As of December 31, 2025, Immix Biopharma had 21 total employees, including 18 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
21
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,665,846
Market Cap
618.34M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | 0 | - | 21 | 0 |
| Dec 31, 2024 | 21 | 4 | 23.53% | 18 | 3 |
| Dec 31, 2023 | 17 | 6 | 54.55% | 14 | 3 |
| Dec 31, 2022 | 11 | 9 | 450.00% | 9 | 2 |
| Dec 31, 2021 | 2 | - | - | 2 | 0 |
| Sep 30, 2021 | 2 | - | - | 2 | 0 |
| Jun 30, 2021 | 2 | - | - | 2 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| 4D Molecular Therapeutics | 196 |
| Ocugen | 116 |
| Prelude Therapeutics | 79 |
| Upstream Bio | 75 |
| Prothena Corporation | 67 |
| Contineum Therapeutics | 51 |
| Shattuck Labs | 40 |
IMMX News
- 1 hour ago - Immix Biopharma price target raised to $20 from $15 at H.C. Wainwright - TheFly
- 1 day ago - Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock - GlobeNewsWire
- 1 day ago - Immix Biopharma’s NXC-201 reaches 95% complete response rate in AL amyloidosis - TheFly
- 1 day ago - Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 - GlobeNewsWire
- 15 days ago - Immix Biopharma Quarterly report: Q1 2026 - Filings
- 22 days ago - Immix Biopharma Slides: Corporate presentation - Filings
- 6 weeks ago - Immix Biopharma to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Immix Biopharma Proxy statement: Proxy filing - Filings